NasdaqHealth CarePharmaceutical PreparationsTORONTO, Ontario, Canada

Edesa Biotech, Inc. EDSA

Ask your AI

Estimated market cap $18.70M9.64M shares, shares as of Aug 13, 2026CIK 1540159

Insider trades, 12 mo

9 buys · 0 sells

$233.0K bought, open market

Congress trades, 24 mo

—

No disclosed trades

13F holders, Q2 2026

38.9% of shares · 7 added

13F holders

…

Lobbying, 12 mo

—

No lobbying filings

Federal contracts, 12 mo

—

None matched

Ask your AI:

Latest 10-Q

Q2 2026

What changed in Edesa Biotech, Inc.'s latest quarterly report, compared with the one before.

Filed Aug 13, 2026 · Quarter ended Jun 30, 2026

Compared with the 10-Q for the quarter ended Mar 31, 2026. Sections compared: management's discussion, risk factors, legal proceedings and controls and procedures.

Read the 10-Q on sec.gov ↗Filing index ↗

Latest 10-Q

What changed in Edesa Biotech, Inc.'s latest quarterly report, compared with the one before.

Loading…

Insider trades

9 in 12 mo

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

No open-market insider trades reported since Mar 10, 2026. Insiders have two business days to file.

Recent insider trades

Michael J. Brooks President	Feb 26 Form 4 ↗	Buy	+$3,140 2,000 sh @ $1.57	+15.7%
Pardeep Nijhawan Chief Executive Officer, Director, 10% owner	Mar 10 Form 4 ↗	Buy	+$6,600 1,000 sh @ $6.60	-83.3%
Pardeep Nijhawan Chief Executive Officer, Director, 10% owner	Mar 5 Form 4 ↗	Buy	+$39.0K 10,000 sh @ $3.90	-57.0%
Pardeep Nijhawan Chief Executive Officer, Director, 10% owner	Mar 4 Form 4 ↗	Buy	+$42.6K 10,000 sh @ $4.26	-64.7%
Pardeep Nijhawan Chief Executive Officer, Director, 10% owner	Mar 3 Form 4 ↗	Buy	+$36.3K 10,000 sh @ $3.63	-66.3%

All EDSA insider trades →Planned sales (Form 144): see notices

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

Loading…

13F holders

3.75M shares

33 funds report EDSA. Values checked against market prices.

Funds own 39% of shares (Q2 2026)

33 funds hold the stock.

Q3 2026: 11% · 5,560 of ~8,900 funds reported so far

Q2 202530%
Q3 202541%
Q4 202537%
Q1 202630%
Q2 202639%
Q3 2026 (so far)11%

Reports for the quarter ending Sep 30, 2026 are still coming in (17 positions so far, against 35 the quarter before), so we compare the two complete quarters before it.

Q2 2026. 10 new, 7 added to, 5 trimmed, 6 exited since Q1 2026.

Top 13F holders
#
1	Velan Capital Investment Management LP 13F ↗	827,500	$6.7M	unchanged
2	Rubric Capital Management LP 13F ↗	669,500	$5.4M	-2.6%
3	Perceptive Advisors LLC 13F ↗	563,239	$4.6M	unchanged
4	Millennium Management LLC 13F ↗	561,751	$4.6M	New
5	Stonepine Capital Management, LLC 13F ↗	456,439	$3.2M	+1421.5%
6	Boxer Capital Management, LLC 13F ↗	205,000	$1.7M	New
7	Vanguard Capital Management LLC 13F ↗	81,839	$665.4K	-4.8%
8	Geode Capital Management, LLC 13F ↗	80,879	$657.6K	+5.0%
9	Jane Street Group, LLC 13F ↗	72,465	$589.1K	-37.4%
10	Vanguard Fiduciary Trust Co 13F ↗	38,718	$314.8K	+0.7%

Download CSV Every fund that holds EDSA, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

13F holders

Funds that report this stock, checked against market prices.

Loading…

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

No recent congressional trades for this company.

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

Loading…

Lobbying

What Edesa Biotech, Inc. and its lobbying firms report each quarter.

No recent lobbying filings for this company.

Lobbying

What Edesa Biotech, Inc. and its lobbying firms report each quarter.

Loading…

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Funds holding the stock

Shares they report

Funds holding the stock by quarter

Q4 2023	19	—	110,873	$507.2K
Q1 2024	17	-2	107,936	$451.1K
Q2 2024	17	0	150,715	$645.1K
Q3 2024	18	+1	161,349	$718.2K
Q4 2024	17	-1	207,514	$350.1K
Q1 2025	20	+3	2.82M	$6.9M
Q2 2025	20	0	2.11M	$4.3M
Q3 2025	23	+3	2.88M	$7.1M
Q4 2025	22	-1	3.05M	$4.3M
Q1 2026	28	+6	2.64M	$13.8M
Q2 2026	33	+5	3.75M	$30.0M
Q3 2026	17	-16	1.05M	$4.4M

Each point is a quarter-end, from Q4 2023 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.

Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.

The history follows the company's current CUSIP number (27966L306). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q4 2023) can be later than the stock's first appearance in 13F reports.

Share counts are adjusted for stock splits; none took place between these quarters. Values are in dollars as reported at the time and are not adjusted.

A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Loading…

More filings and data

Each opens the table.

Ownership stakes17 in 12 mo 8-K events4 in 90 days Patents2 patents granted Short interestFINRA · updated Oct 15 Planned insider salesNone in 12 mo Executive payNone on record Wikipedia attentionNone on record SEC enforcementNone on record Clinical trials1 active IPO history4 registrations Ownership stakes…8-K events…Patents…Short interest…Planned insider sales…Executive pay…Wikipedia attention…SEC enforcement…

About the company

The basics from the company’s SEC registration.

Legal name: Edesa Biotech, Inc.
Address: C/O FASKEN MARTINEAU DUMOULIN LLP, 333 BAY STREET, SUITE 2400, TORONTO, Ontario, Canada M5H 2T6
Phone: (905) 475-1234
Fiscal year ends: Sep 30
Filer category: Non-accelerated filer, smaller reporting company
Incorporated in: British Columbia, Canada
Listed as: EDSA (Nasdaq)
Former names: Stellar Biotechnologies, Inc. (until 2019)
SEC filings: All filings on SEC EDGAR ↗

About the company

The basics from the company’s SEC registration.

Loading…

$1.94−$0.14 (−6.73%) Nov 13 close

1M3M1Y

Oct 13, 2026Low $1.94 · High $2.85Nov 13, 2026

Aug 13, 2026Low $1.94 · High $5.75Nov 13, 2026

Nov 13, 2025Low $0.80 · High $18.28Nov 13, 2026

Congress purchase Congress sale Insider sale over $1M

Adjusted for stock splits; not for dividends. Where prices come from.

Live chart

Intraday and historical prices from TradingView. Quotes may be delayed.

Loading chart…

Information, not investment advice. Company matching is automatic; check the source before relying on one row.